Specific concerns for Crohn's patients include: Nausea and vomiting : May exacerbate existing symptoms or lead to dehydration, particularly concerning in patients with active disease Diarrhea : Difficult to differentiate from Crohn's-related diarrhea, potentially delaying recognition of disease flares Abdominal pain : May mask or mimic Crohn's-related pain, complicating clinical assessment Reduced oral intake : Appetite suppression combined with nausea may worsen nutritional deficiencies common in IBD Additional FDA-labeled risks include: Acute gallbladder disease : Cholelithiasis and cholecystitis occur more frequently with semaglutide, particularly with rapid weight loss [12] [15] Acute kidney injury : Dehydration from gastrointestinal side effects may lead to kidney injury Pancreatitis : Patients should be monitored for severe, persistent abdominal pain, sometimes radiating to the back Rare but serious gastrointestinal adverse events reported in post-marketing surveillance include cases of bowel obstruction and ileus

Patients with end-stage renal disease were excluded from this analysis
Interesting, can you say more about that
Current guidelines recommend discontinuing GLP-1 medications before conception and using alternative treatments like insulin during pregnancy
Lifestyle Adjustments Mitigation Strategies: Resistance training maintains muscle under diminished fat, which provides skin scaffolding, so seek 2 to 4 strength sessions per week
However, not every patient needs the highest dose